Subscribe To

Price Alert Latest News Economic Calendar News

CING / Cingulate Outlines Plan For Pivotal Attention Deficit/Hyperactivity Disorder Studies

Cingulate Inc CING plans to initiate Phase 3 studies for CTx-1301 for Attention Deficit/Hyperactivity Disorder (ADHD) in 2022. Get the Inside Access Traders Are Using to Profit More and Win Bigger. Read More

Demo Live Account See Partner Details

Content Topics

Hoteles

City

Express

De

Hcity

Mx

Cingulate

Outlines

Pivotal

Attention

Deficit hyperactivity

Disorder

Studies

Stock

CING

Posted: Feb 8 2022, 12:20

Author Name: Benzinga

CING News

By Newsfile Corp
September 21, 2023

Cingulate Inc. To Present at the LD Micro Main Event XVI

Presentation on Wednesday, October 4th at 02:30 PM PT Kansas City, Kansas--(Newsfile Corp. - September 21, 2023) - Cingulate Inc. (NASDAQ: CING), a bi

By GlobeNewsWire
June 14, 2023

Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest

KANSAS CITY, Kan., June 14, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Ti

By GlobeNewsWire
May 25, 2023

Cingulate to Present at 13th Annual LD Micro Invitational

KANSAS CITY, Kan., May 25, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Tim

By PennyStocks
February 27, 2023

Building a Penny Stocks Portfolio For Long Term

Use these tips for buying penny stocks for the long term The post Building a Penny Stocks Portfolio For Long Term appeared first on Penny Stocks to

By InvestorPlace
February 24, 2023

Why Is Cingulate (CING) Stock Up 72% Today?

Cingulate (NASDAQ: CING ) stock is on the rise Friday after releasing positive data concerning its ADHD treatment. The big news today is Cingulate's C

By Newsfile Corp
November 3, 2022

Cingulate Inc. to Present at Investor Summit Group's Q4 Conference

Kansas City, Kansas--(Newsfile Corp. - November 3, 2022) - Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precis

By GlobeNewsWire
May 18, 2022

Cingulate to Present at H.C. Wainwright Global Investment Conference

KANSAS CITY, Kan., May 18, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietar

By Benzinga
February 8, 2022

Cingulate Outlines Plan For Pivotal Attention Deficit/Hyperactivity Disorder Studies

Cingulate Inc CING plans to initiate Phase 3 studies for CTx-1301 for Attention Deficit/Hyperactivity Disorder (ADHD) in 2022. Get the Inside Acces

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.